Kane v. Winn

319 F. Supp. 2d 162, 2004 U.S. Dist. LEXIS 10027, 2004 WL 1179345
CourtDistrict Court, D. Massachusetts
DecidedMay 27, 2004
DocketCIV.A.03-40116-WGY
StatusPublished
Cited by24 cases

This text of 319 F. Supp. 2d 162 (Kane v. Winn) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kane v. Winn, 319 F. Supp. 2d 162, 2004 U.S. Dist. LEXIS 10027, 2004 WL 1179345 (D. Mass. 2004).

Opinion

MEMORANDUM

YOUNG, Chief Judge.

I. INTRODUCTION

If incarceration rates remain unchanged, 6.6% of U.S. residents born in 2001 will go to prison at some time during their lifetime. 1

This memorandum explores the consequences of this statistic, which stark as it is, does not even account for incarceration in jails or growing incarceration rates. The particular action here involved a federal prisoner’s allegations that his medical treatment fell short of what Bureau of Prisons (“BOP”) regulations and the United States Constitution require, and that the BOP retaliated against him for requesting adequate medical care. The prisoner, Michael Kane (“Kane”), moved for appointment of counsel and requested a jury trial. Kane and Federal Medical Center-Devens Warden David L. Winn (“Warden”) filed cross motions for summary judgment.

For the reasons discussed below, Kane’s Motions for Appointment of Counsel [Doc. No. 14], for a Jury Trial [Doc. No. 5], and for Summary Judgment [Doc. No. 11] were DENIED, the Warden’s Motion for Summary Judgment [Doc. No. 7] was ALLOWED, judgment was entered for the Warden, and no further filing fee was assessed.

II. BACKGROUND

A. Factual Background

1. Kane’s Incarceration and Medical Condition

On March 23, 2000, the United States District Court for the Eastern District of Pennsylvania sentenced Kane to ten years in prison followed by five years of supervised release for distribution of metham-phetamines, a violation of 21 U.S.C. 841(a)(1). Def.’s 56.1 Stmt. [Doc. No. 8] ¶ 1; id. Ex. 1, Attach. A. 2 On January 4, *167 2001, he was transferred to Federal Medical Center-Devens (“FMC-Devens”) in Ayer, Massachusetts, where he remains incarcerated. Id. ¶ 1; id. Ex. 1, Attach. F.

Kane, a 47-year-old man, id. Ex. 2 (Letter from Hinendi and Guzman to Howard of 2/11/02) [hereinafter “Hinendi Letter”], has a history of hepatitis B and C, diabetes mellitus type I, 3 seizure disorder, asthma, gastroesophageal reflux disease, and peptic ulcer disease. Id. Ex. 1, Attach. C (Response to Request for Administrative Remedy #241172-F1 of 6/15/01). He has chronic hepatitis C, and was apparently first diagnosed with hepatitis C about five years ago. Id. Ex. 2. His hepatitis C virus (“HCV”) genotype is 1 (1A, to be precise). Id. Ex. 1, Attach. G (Algorithm for Treatment of Hepatitis C/Approval Form of 3/6/03). He is overweight, has a history of heavy drinking, and smokes. Id.

2. Nature, Monitoring, and Treatment of Chronic Hepatitis C

a. Nature of Chronic Hepatitis C

An understanding of chronic hepatitis C is necessary to an evaluation of Kane’s claims. HCV is an RNA virus, transmitted primarily through the blood, and which mainly impacts the liver. Def.’s 56.1 Stmt. Ex. 3, at 8 (National Institutes of Health Consensus Development Conference Statement — Management of Hepatitis C: 2002 (June 10-12, 2002), at 3-4, at http:// odp.od.nih.gov/consensus/cons/116/116 cdc_intro.htm (last modified Sept. 12, 2002) [hereinafter NIH Statement ]). It is difficult for the body’s immune system to eradicate. Id. Ex. 4 (Nelson Decl.) ¶ 5. It resides in liver cells (hepatocytes), where it replicates and causes cell death (necrosis). Id. Infection becomes chronic if it persists for at least six months. NIH Statement, supra, at 4.

According to the National Health and Nutrition Examination Survey of 1988— 1994, as of 1994, 3.9 million Americans were infected with HCV, an estimated 2.7 million of whom were suffering from chronic infection. Id. at 3. That population-based household survey almost certainly underestimated levels of infection, as it did not include the incarcerated, the institutionalized, or the homeless, among all of whom the disease is more prevalent than in the population at large. Id. An estimated 35,000 new HCV infections occur every year, and HCV is the most common blood-borne infection nationwide. Id. at 4.

As Harrison’s Principles of Internal Medicine, a medical treatise that both Kane and the Warden cite as an accurate scientific reference, describes: “Milder forms [of chronic hepatitis] are nonpro-gressive or only slowly progressive, while more severe forms may be associated with scarring and architectural reorganization, which, when advanced, lead ultimately to cirrhosis.” Jules L. Dienstag & Kurt J. Isselbaeher, Chronic Hepatitis, in 2 Harrison’s Principles of Internal Medicine 1742, 1742 (Eugene Braunwald et al. eds., 15th ed.2001) [hereinafter Chronic Hepatitis ]. Twenty percent of those with chronic transfusion-associated hepatitis C (a class that may include Kane) progress to cirrhosis. Id. at 1747. Hepatocellular carcinoma (“HCC”) can follow, 4 as can end- *168 stage liver disease and liver failure. NIH Statement, supra, at 4; Chronic Hepatitis, supra, at 1747. At least 10,000 to 12,000 deaths result from hepatitis C each year. NIH Statement, supra, at 5.

Progression of liver disease in chronic hepatitis C patients is more likely “in patients with older age, longer duration of infection, advanced histologic stage and grade, genotype 1 (especially type lb), more complex quasispecies diversity, 5 and increased hepatic iron.” Chronic Hepatitis, supra, at 1747 (footnote added). Duration of infection appears to be the most important of this set of variables, and several of the other factors, such as quasispe-cies diversity and hepatic iron accumulation, “probably reflect disease duration to some extent.” Id. Of lesser but still substantial significance is the severity of grade and stage; patients with mild grade and stage tend not to progress to cirrhosis, whereas for patients with moderate or severe grade and stage, “progression to cirrhosis is highly likely over the course of 10 to 20 years.” Id. Patients who simultaneously suffer from other liver processes, such as chronic hepatitis B, 6 alcoholic liver disease, and hemochromatosis, are also prone to greater severity of chronic hepatitis and faster progression of chronic liver disease. Id.

Still, for the majority of patients, the long-term prognosis is “relatively benign”:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Commonwealth v. Roberto Lopez-Ortiz
Massachusetts Appeals Court, 2025
Alvarez Mendoza v. Moniz
D. Massachusetts, 2023
McFadden v. Burke
D. Massachusetts, 2023
Savino v. Hodgson
D. Massachusetts, 2020
Commonwealth v. Colon
121 N.E.3d 1157 (Massachusetts Supreme Judicial Court, 2019)
Mattingley v. Spalding
D. Massachusetts, 2018
Warner v. Spaulding
D. Massachusetts, 2018
Sperling v. Grondolsky
D. Massachusetts, 2018
Aldrich v. Maceachern
880 F. Supp. 2d 271 (D. Massachusetts, 2012)
Graham v. Sabol
734 F. Supp. 2d 194 (D. Massachusetts, 2010)
Chao v. Ballista
630 F. Supp. 2d 170 (D. Massachusetts, 2009)
Kogut v. Ashe
592 F. Supp. 2d 204 (D. Massachusetts, 2008)
ILINA v. Zickefoose
591 F. Supp. 2d 145 (D. Connecticut, 2008)
Hollis v. Director of Corrections
560 F. Supp. 2d 920 (C.D. California, 2008)
Graham v. State
982 So. 2d 43 (District Court of Appeal of Florida, 2008)
Sanchez v. Sabol
539 F. Supp. 2d 455 (D. Massachusetts, 2008)
Muniz v. Winn
462 F. Supp. 2d 175 (D. Massachusetts, 2006)
Fox v. Lappin
441 F. Supp. 2d 203 (D. Massachusetts, 2005)
Enwonwu v. Chertoff
376 F. Supp. 2d 42 (D. Massachusetts, 2005)
Simmat v. United States Bureau of Prisons
413 F.3d 1225 (Tenth Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
319 F. Supp. 2d 162, 2004 U.S. Dist. LEXIS 10027, 2004 WL 1179345, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kane-v-winn-mad-2004.